Pathophysiology and treatment of obesity hypertension

Current Pharmaceutical Design

Volumn 10, Issue 29, 2004, Pages 3621-3637

  Wofford, Marion R ^a   Hall, John E ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOBESITY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DEXFENFLURAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FENFLURAMINE; HYDROCHLOROTHIAZIDE; INSULIN; LEPTIN; LISINOPRIL; NIFEDIPINE; PLACEBO; PRAZOSIN; PROOPIOMELANOCORTIN; RENIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADRENERGIC SYSTEM; ANGIONEUROTIC EDEMA; BEHAVIOR MODIFICATION; BLOOD PRESSURE REGULATION; BLOOD VOLUME; BODY WEIGHT DISORDER; CLINICAL TRIAL; COMPRESSION; CONGESTIVE HEART FAILURE; COUGHING; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; ESSENTIAL HYPERTENSION; FATIGUE; GASTROINTESTINAL DISEASE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOTHALAMUS; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; LIFESTYLE; METABOLIC SYNDROME X; MORBID OBESITY; NATRIURESIS; OBESITY; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; SEDATION; SLEEP APNEA SYNDROME; SODIUM RESTRICTION; SOMNOLENCE; STOMACH BYPASS; TACHYCARDIA; TIME; TREATMENT OUTCOME; VALVULAR HEART DISEASE; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ENDOTHELIUM, VASCULAR; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; LIFE STYLE; OBESITY; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

EID: 6344226830     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043382855     Document Type: Review

References (144)

1. World Health Organization. Obesity epidemic puts millions at risk from related diseases [press Release WHO/46, 12 June 1997. Available at: http://www.who.int/archives/inf-pr-1997/en/pr97-46.html
2. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288: 1723-7.
3. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, JAMA 1999-2000; 288: 1728-32.
4. World Health Organization. Obesity and Overweight. http://www.who.int/hpr/NPH/docs/gs_obesity.pdf
5. Sorof J, Daniels S: Obesity hypertension in children - a problem of epidemic proportions. Hypertension 2002; 40: 441-447.
6. Huang Z, Willett WC, Manson JE, et al. Body weight, weight change, and risk for hypertension in women. Ann Intern Med. 1998; 128: 81-88.
7. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993; 119 (7 pt 2); 655-660.
8. National Institutes of Health, National Heart, Lung and Blood Institutes. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res 1998; 6: S2.
9. Wilson PWF, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk - the Framingham experience. Arch Intern Med 2002; 162: 1867-1872.
10. Hall JE, Crook ED, Jones DW, et al. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002, 324(3): 127-137.
11. Hall JE, Jones DW, Kuo JJ, da Silva A, Tallam LS, Liu J. Impact of obesity on hypertension and renal disease. Current Hypertension Reports 2003; 5: 386-392.
12. Wannamethee SG, Shaper AG: Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care 1999; 22(8): 1266-1272.
13. Sundquist J, Winkeby MA, Pudaric S: Cardiovascular disease risk factors among older Black, Mexican-American, and white women and men: an analysis of NHANES III; 1988-1994. J Am Geriatr Soc 2001; 49: 109-116.
14. He Q, Ding YZ, Fong DY, Karlberg J: Blood Pressure Is Associated With Body Mass Index in Both Normal and Obese Children. Hypertension 2000; 36: 165-170.
15. Garrison RJ, Kannel WB, Stokes J, et al. Incidence and precursors of hypertension in young adults: The Framingham Offspring Study. Prev Med 1987; 16(2): 235-251.
16. Ruhl CE, Everhart JE. Leptin concentrations in the United States: relations with demographic and anthropometric measures. Am J Clin Nutr 2001; 74: 295-301.
17. Jones DW, Kim JS, Andrew ME et al. Body mass index and blood pressure in Korean men and women: the Korean national blood pressure survey. J Hypertens 1994; 12: 1433-1437.
18. Dyer AR, Elliott P. The INTERSALT study: relations of body mass index to blood pressure. INTERSALT Cooperative Research Group. J Hum Hypertens 1989; 3: 299-308.
19. Cooper RS, Rotimi CN, Ward R: The puzzle of hypertension in African-Americans. Sci Am 1999; 280: 56-63.
20. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358: 1682-1686.
21. Rexrode KM, Manson JE, Hennekens CH. Obesity and cardiovascular disease. Curr Opin Cardiol 1996; 11: 490-495.
22. Juhaeri, Stevens J, Chambless LE, Tyroler JA, Rosamond W, Nieto FY, et al. Associations between weight gain and incident hypertension in a bi-ethnic cohort: the Atherosclerosis Risk in Communities Study. Int J Obes Relat Metab Disord 2002; 26: 58-64.
23. Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith West D, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Annals Internal Medicine 2001, 134(1): 1-11.
24. Jones DW, Miller ME, Wofford MR, Anderson DC Jr, Cameron ME, Willoughby DL, et al. The effect of weight loss interventions on antihypertensive medication requirements in the Hypertension Optimal Treatment (HOT) Study. American Journal of Hypertension 1999; 12: 1175-1180.
25. He J, Whelton PK, Appel LJ, et al. Long-Term Effects of Weight Loss and Dietary Sodium Reduction on Incidence of Hypertension. Hypertension 2000, 35: 544-549.
26. Hall JE: The Kidney, Hypertension, and Obesity. Hypertension 2003, 41: 625-633.
27. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206-1252.
28. Van Vliet BN, Hall JE, Mizelle HL, et al. Reduced parasympathetic control of heart rate in obese dogs. American Journal of Physiology 1995; 269: H629-H637.
29. Hall JE, Brands MW, Dixon WN, et al. Obesity-induced hypertension: renal function and systemic hemodynamics. Hypertension 1993; 22: 292-299.
30. Rocchini AP, Mao HZ, Babu K, et al. Clonidine prevents insulin resistance and hypertension in obese dogs. Hypertension 1999; 33: 548-553.
31. Messerli FH, Christie B, DeCarvalho JG, et al. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion and plasma renin activity. Archives of Internal Medicine 1981; 141: 81-85.
32. Carroll JF, Braden DS, Cockrell K, et al. Obese rabbits develop concentric and eccentric hypertrophy and diastolic filling abnormalities. American Journal of Hypertension 1997; 10: 230-233.
33. Alpert MA. Obesity cardiomyopathy and the evolution of the clinical syndrome. American Journal of Medical Sciences 2001; 321: 225-236.
34. Gottdiener JS, Reda DJ, Materson BJ, et al. Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. Journal of the American College of Cardiology 1994; 24: 1492-1498.
35. Carroll JF, Summers RL, Dzielak DJ, et al. Diastolic compliance is reduced in obese rabbits. Hypertension 1999; 33: 811-815.
36. Unger RH. Weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003; 144: 5159-5165.
37. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-313.
38. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-2610.
39. Raitakari M, Ilvonen T, Ahotupa M, Lehtimaki T, Harmoinen A, Suominen P, et al. Weight reduction with very low-caloric diet and endothelial function in overweight adults: role of plasma glucose. Arterioscler Thromb Vasc Biol 2004; 24: 124-128.
40. Wildman RP, Mackey RH, Bostom A, Thompson T, Sutton-Tyrrell K. Measures of obesity are associated with vascular stiffness in young and older adults. Hypertension 2003; 42: 468-473.
41. Tounian P, Aggoun Y, Dubern B, Varille V, Guy-Grand B, Sidi D, et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet 2001: 358: 1400-1404.
42. Lyon CJ, Law RE, Hsueh WA. Adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144: 2195-2200.
43. Hall JE. Mechanisms of abnormal renal sodium handling in obesity hypertension. American Journal of Hypertension 1997; 10: s49-s55.
44. Eslami P, Tuck M. The role of the sympathetic nervous system in linking obesity with hypertension in white versus black Americans. Curr Hypertens Rep 2003; 5: 269-272.
45. Landsberg L, Krieger DR. Obesity, metabolism, and the sympathetic nervous system. American Journal of Hypertension 1989; 2: 1255-1325.
46. Rumantir MS, Vaz M, Jennings GL, Collier G, et al. Neural mechanisms in human obesity-related hypertension. Journal of Hypertension 1999; 17: 1125-1133.
47. Esler M. The sympathetic system and hypertension. American Journal of Hypertension 2000; 13: 99s-105s.
48. Grassi G, Servalle G, Cattaneo BM, et al. Sympathetic activity in obese normotensive subjects. Hypertension 1995; 25: 560-563.
49. Weyer C, Pratley RE, Snitker S, et al. Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension 2000; 36(4): 531-537.
50. Abate NI, Mansour YH, Arbique D, et al. Overweight and sympathetic activity in black Americans. Hypertension 2001; 38: 379-383.
51. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity. Circulation 2002; 106: 2533-2536.
52. Rocchini AP, Mao HZ, Babu K, et al. Clonidine prevents insulin resistance and hypertension in obese dogs. Hypertension 1999; 33: 548-553.
53. Antic V, Kiener-Belforti F, Tempini A, et al. Role of the sympathetic nervous system during the development of obesity hypertension in rabbits. American Journal of Hypertension 2000; 13: 556-559.
54. Wofford MR, Anderson DC, Brown CA, et al. Antihypertensive effect of alpha and beta adrenergic blockade in obese and lean hypertensive subjects. American Journal of Hypertension 2001; 14: 164-168.
55. Kassab S, Kato T, Wilkins C, et al. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995; 25: 893-897.
56. Landsberg L, Krieger DR. Obesity, metabolism, and the sympathetic nervous system. Am J Hypertens 1989; 2(suppl 2): 125S-132S.
57. Hall JE. Hyperinsulinemia: A link between obesity and hypertension? Kidney International 1993; 43: 1402-1417.
58. Narkiewicz K, Kato M, Pesek CA, et al. Human obesity is characterized by selective potentiation of central chemoreflex sensitivity. Hypertension 1999; 33: 1153-1158.
59. Wolk R, Shamsuzzaman ASM, Somers VK. Obesity, sleep apnea, and hypertension. Hypertension 2003; 42: 1067-1074.
60. Grassi G, Seravalle G, Dell'Oro R, et al. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 2000; 36: 538-542.
61. Hall JE, Hildebrandt DA, Kuo JJ. Obesity hypertension: role of leptin and sympathetic nervous system. American Journal of Hypertension 2001; 14: 103s-115s.
62. Jequier E. Leptin signaling, adiposity, and energy balance. Ann NY Acad Sci 2002; 967: 379-388.
63. Correia MLG, Morgan DA, Sivitz WI, et al. Leptin acts in the central nervous system to produce close-dependent changes in arterial pressure. Hypertension 2001; 27: 936-942.
64. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998; 31: 409-414.
65. Kuo J, Jones OB, Hall JE. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension 2001; 37: 670-676.
66. Carlyle M, Jones OB, Kuo JJ, Hall JE. Chronic cardiovascular and renal actions of leptin-role of adrenergic activity. Hypertension 2002; 39: 496-501.
67. Mark AL, Shaffer RA, Correia ML, et al. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow mice. J Hypertens 1999; 17: 1949-1953.
68. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine detects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 1999; 10: 3686-3695.
69. Haynes WG, Morgan DA, Djalali A, et al. Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension 1999; 33: 542-547.
70. da Silva, AA, Kuo JJ, Hall JE. Role of hypothalamic melanocortin 3/4-receptors in mediating chronic cardiovascular, renal and metabolic actions of leptin. Hypertension (in Press).
71. Kuo JJ, Silva AA, Hall JE. Hypothalamic melanocortin receptors and chronic regulation of arterial pressure and renal function. Hypertension 2003; 41: 768-774.
72. Engeli S, Sharma AM. The renin angiotensin system and natriuretic peptides in obesity associated hypertension. Journal of Molecular Medicine 2001; 79: 21-29.
73. Hall JE, Henegar JR, Shek EW, et al. Role of renin-angiotensin system in obesity hypertension. Circulation 1997; 96: 1-33 (Abstract).
74. Robles RG, Villa E, Santirso R, et al. Effects of captopril on sympathetic activity, lipid and carbohydrate metabolism in a model of obesity-induced hypertension in dogs. American Journal of Hypertension 1993; 6: 1009-1019.
75. Reisen E, Weir M, Falkner B, et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: A multicenter placebo-controlled trial. Hypertension 1997: 30: 140-145.
76. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.
77. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
78. Kurtz TW. False claims of blood pressure-independent protection by blockade of the renin angiotensin aldosterone system? Hypertension 4: 193-196, 2003.
79. Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001; 12: 308-314.
80. de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004; 43: 41-47.
81. Sugarman HJ, Windsor ACJ, Bessos MK, et al. Intra-abdominal pressure, sagittal abdominal diameter and obesity co-morbidity. Journal of Internal Medicine 1997; 241: 71-79.
82. Hall JE, Henegar JR, Dwyer TM, Liu J, da Silva AA, Kuo JJ, et al. Is obesity a major cause of chronic renal disease? Advance Renal Replacement Therapy 2004; 11: 41-54.
83. Henegar JR, Bigler SA, Henegar LK, et al. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001; 12: 1211-1217.
84. Morales E, Valero MA, Leon M, et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003; 41: 319-327.
85. Kambham N, Markowitz GS, Valeri AM, et al. Obesity related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59; 1498-1509.
86. Praga M, Hernandez E, Herrero JC, et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 2000; 58: 2111-2118.
87. Bonnet F, Deprele C, Sassolas A, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001; 37: 720-727.
88. Sturm R. The effects of obesity, smoking and drinking on medical problems and costs. Obesity outranks both smoking and drinking in its deleterious effects on health and health costs. Health Affairs 2002; 21: 245-253.
89. The Trials of Hypertension Prevention Collaborative Research Group. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. JAMA 1992; 267: 1213-1220.
90. Whelton PK, Appel LJ, Espeland MA, et al. For the TONE Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons: A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA 1998; 279: 839-846.
91. Davis BR, Blaufoz MD, Oberman A, et al. Reduction in long-term antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild hypertension. Archives of Internal Medicine 1993; 153: 1773-1782.
92. Imai Y, Sato K, Abe K, et al. Effects of weight loss on blood pressure and drug consumption in normal weight patients. Hypertension 1986; 8: 223-228.
93. Stamler R, Stamler J, Gosch R, et al. Primary prevention of hypertension by nutritional-hygienic means. Final report of a randomized, controlled trial. JAMA 1989; 262: 1801-1807.
94. Metz JA, Stearn JS, Kris-Etherton P, et al. A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. Arch Intern Med 2000, 160: 1947-1958.
95. Reisin E, Frohlich ED, Messerli FH, et al. Cardiovascular changes after reduction in obesity hypertension. Ann Intern Med 1983; 98: 315-319.
96. Tuck ML et al. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Eng J Med 1981; 304: 930-933.
97. Galuska DA, Will JC, Serdula MK, et al. Are health care professionals advising obese patients to lose weight? JAMA 1999; 282: 1576-1578.
98. Serdula MK, Mokdad AH, Williamson DF, et al. Prevalence of attempting weight loss and strategies for controlling weight. JAMA 1999; 282: 1353-1358.
99. Zhu S, Wang Z, Heshka S, Heo M, Faith MS, Heymsfield SB. Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds. Am J Clin Nutr 2002; 76: 743-749.
100. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 16; 285: 2486-2497.
101. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention (Phase II). Arch Intern Med 1997; 157: 657-667.
102. Sacks FM, Brown LE, Appel L, Borhani NO, Evans D, Whelton P. Combinations of potassium, calcium and magnesium supplement in hypertension. Hypertension 1995; 26: 950-956.
103. Lopes HF, Martin KL, Nashar K, Morrow JD, Goodfriend TL, Eagan BM. DASH diet lowers blood pressure and lipid induced oxidative stress in obesity. Hypertension 2003; 41: 422-430.
104. He J, Ogden LG, Vupputuri S, Bazzano LA, Loria C, Whelton PK. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. JAMA 1999; 282: 2027-2034.
105. Blair SM, Goodyear NN, Gibbons LW, Copper KH. Physical fitness and incidence of hypertension in healthy normotensive men and women. JAMA 1984; 52: 487-490.
106. Paffenbarger RS Jr, Hyde RT, Wing AL, Lee IM, Jung DL, Kambert JB. The association of changes in physical- activity level and other lifestyle characteristics with mortality among men. N Eng J Med 1993; 328: 538-545.
107. Dunn AL, Marcus BH, Kampert JB, Garcia ME, Kohl HW 3rd, Blair SN. Comparison of lifestyle and structured interventions to increase physical activity and cardiorespiratory fitness: a randomized trial. JAMA 1999; 281: 327-334.
108. Arakawa K. Antihypertensive mechanisms of exercise. J Hypertens 1993; 11: 223-229.
109. Blumenthal JA, Sherwood A, Gullette EC, Babyak M, et al. Exercise and weight loss reduce blood pressure in men and women with mild hypertension: effects on cardiovascular, metabolic, and hemodynamic functioning. Arch Intern Med 2000; 160: 1947-1958.
110. Connally AM, Crary JL, McGoon MP, et al. Valvular heart disease associated with fenfluramine-phentermine. N Eng J Med 1997; 337: 581-588.
111. Jones SP, Smith IG, Keffy F, Gray JA. Long term weight loss with sibutramine. Int J Obes 1995; 19(Suppl 2): 41 [abstract 071].
112. Bray GA, Ryan DH, Gordon D, et al. Double-blind, randomized, placebo-controlled trial of sibutramine. Obes Res 1996; 4: 263-270;
113. Knoll Pharmaceutical Company. Package literature for Meridia®. January 1998.
114. Roche Pharmaceuticals. Package literature for Xenical®. April 1999.
115. Reaven G, Segal K, Hauptman J, Boldrin M, Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease in patients with syndrome X. Am J Cardiol 2001; 87: 827-831.
116. Sharma AM, Golay A. Effect of orlistat-induccd weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002; 20: 1873-1878.
117. Koch R, Sharma AM. Obesity and cardiovascular hemodynamic function. Curr Hypertens Rep 1999; 1: 127-30.
118. Groop L. Pathogenesis of type 2 diabetes: the relative contribution of insulin resistance and impaired insulin secretion. Int J Clin Pract Suppl 2000; 113: 3-13.
119. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle and the risk of type 2 diabetes mellitus in women. N Eng J Med 2001, 345: 790-797.
120. Pischon T, Sharma, AM, Optimizing blood pressure control in the obese patient. Current Hypertension Reports 2002, 4: 358-362.
121. Reisin E, Weir MR, Falkner B, Hutchinson HG, Anzalone DA, Tuck ML. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997; 30: 140-145.
122. Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, Inenaga T, et al. Determinants of circadian blood pressure rhythm in essential hypertension. Am J Hypertens 1999; 1235-1239.
123. Weir MT, Reisin E, Falkner B, Hutchinson HG, Sha L, Tuck ML. Nocturnal reduction of blood pressure and the antihypertensive response to a diuretic or angiotensin converting enzyme inhibitor in obese hypertensive patients. Am J Hypertens 1998; 11: 914-920.
124. Hypertension in Diabetes Study. III. Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibition and beta-blockade. Diabet Med 1994; 11: 773-782.
125. Gambardella S, Frontoni S, Pellegrinotti M, Testa G, Spallone V, Menzinger G. Carbohydrate metabolism in hypertension: influence of treatment. J Cardiovasc Pharmacol 1993; 22: S87-S99.
126. Gress TW, Nieto FJ, Shahar E, Wofford MR, Branchati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000 30; 342: 905-912
127. Sharma AM, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens 2001; 19: 667-674.
128. Dahlof B, Zanchetti AS, Diez J, Nicholls MD, et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20: 1855-1864.
129. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-1886.
130. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
131. Tuck ML, Brava EL, Krakoff LR, Friedman CP. Endocrine and renal effects of nifedipine gastrointestinal therapeutic system in patients with essential hypertension. Results of a multicenter trial. The Modern Approach to the Treatment of Hypertension Study Group. Am J Hypertens 1990; 3: 333S-341S.
132. Campese VM, Roumoff M, Telfer N, Weidmann P, Massry SG. Role of sympathetic nerve inhibition and body sodium-volume state in the antihypertensive action of clonidine in essential hypertension. Kidney Int 1980; 18: 351-357.
133. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988; 31: 415-420.
134. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283: 1967-1975.
135. Wolk R, Shamsuzzaman AS, Somers VK. Obesity, sleep apnea, and hypertension. Hypertension 2003; 42: 1067-1074.
136. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study: Sleep Heart Health Study. JAMA 2000; 283: 1829-1836.
137. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342: 1378-1384.
138. Weiss JW, Remsburg S, Garpestad E, Ringler J, Sparrow D, Parker JA. Hemodynamic consequences of obstructive sleep apnea: state of the art review. Sleep 1996: 19: 388-397.
139. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 1995; 96: 1897-1904.
140. Kanagy LK, Walker BR, Nelin LD. Role of Endothelin in intermittent hypoxia-induced hypertension. Hypertension 2001; 37: 511-515.
141. Faccenda JF, Mackay TW, Boon NA, Douglas NJ. Randomized placebo controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med 2001; 163: 344-348.
142. Banks WA. Is obesity a disease of the blood-brain barrier? Physiological, pathological, and evolutionary considerations. Curr Pharm Design 2003; 9(10): 801-9.
143. Salvetti A, Versari D. Control of blood pressure in the community: an unsolved problem. Curr Pharm Design 2003; 9(29): 2375-84.
144. Veniant MM, LeBel CP. Leptin: from animals to humans. Curr Pharm Design 2003; 9(10): 811-8.